In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue

This article is powered by The Rose Sheet

Executive Summary

FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.

Advertisement

Related Content

FDA Urged To Crack Down On Supplements For Nicotine Addiction
OTC Tramadol Sales By 21 Online Pharmacies Found In US FDA Sweep
OTC Tramadol Sales By 21 Online Pharmacies Found In US FDA Sweep
Poppy Seed Tea Latest Catch In FDA Enforcement Net For Opioid Claims
Opioid-Withdrawal Beverage Seller Latest Target Of FDA-FTC Joint Enforcement
Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI
Kratom Supplement Marketers Dispute FDA Warning, Ask For Review
Opiate Addiction Remedy Claims Could Face FTC Substantiation Test

Topics

Advertisement
UsernamePublicRestriction

Register

RS121429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel